Ingram, J. W., Chung, R., Laplaca, C., McKiernan, J. M., Lenis, A. T., & Anderson, C. B. (2024). Incidence and management of prostatic urethra recurrence in a cohort of 21 patients who received BCG induction for non-muscle invasive bladder cancer. Urologic Oncology: Seminars and Original Investigations, 42(9), 290.e11-290.e16. https://doi.org/10.1016/j.urolonc.2024.04.017

Chung, R., McKiernan, J., Arpaia, N., Marabelle, A., & Rouanne, M. (2023). Neo-Adjuvant immunotherapies: Bladder cancer as a platform for drug development targeting mucosal immunity. European Journal of Cancer, 187, 58–64. https://doi.org/10.1016/j.ejca.2023.03.037

Lombardo, K. A., Obradovic, A., Singh, A. K., Liu, J. L., Joice, G., Kates, M., Bishai, W., McConkey, D., Chaux, A., Eich, M., Rezaei, M. K., Netto, G. J., Drake, C. G., Tran, P., Matoso, A., & Bivalacqua, T. J. (2021). BCG invokes superior STING‐mediated innate immune response over radiotherapy in a carcinogen murine model of urothelial cancer. The Journal of Pathology, 256(2), 223–234. Portico. https://doi.org/10.1002/path.5830